Last reviewed · How we verify
Conversion from Tacrolimus to Sirolimus
Conversion from tacrolimus to sirolimus involves switching from a calcineurin inhibitor to an mTOR inhibitor, both immunosuppressive agents used to prevent organ rejection.
Conversion from tacrolimus to sirolimus involves switching from a calcineurin inhibitor to an mTOR inhibitor, both immunosuppressive agents used to prevent organ rejection. Used for Prevention of organ rejection in transplant recipients (conversion from tacrolimus), Reduction of tacrolimus-related nephrotoxicity in transplant patients.
At a glance
| Generic name | Conversion from Tacrolimus to Sirolimus |
|---|---|
| Sponsor | Helio Tedesco Silva Junior |
| Drug class | Immunosuppressive agent (conversion protocol) |
| Target | mTOR (mammalian target of rapamycin) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Tacrolimus and sirolimus are both immunosuppressive drugs commonly used in transplant recipients, but they work through different mechanisms. Tacrolimus inhibits calcineurin and T-cell activation, while sirolimus inhibits mTOR and blocks T-cell and B-cell proliferation. The conversion strategy aims to reduce tacrolimus-related nephrotoxicity and other adverse effects while maintaining immunosuppression through an alternative mechanism.
Approved indications
- Prevention of organ rejection in transplant recipients (conversion from tacrolimus)
- Reduction of tacrolimus-related nephrotoxicity in transplant patients
Common side effects
- Hyperlipidemia
- Thrombocytopenia
- Anemia
- Delayed wound healing
- Mouth ulcers
- Pneumonitis
Key clinical trials
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation (PHASE1, PHASE2)
- Liver Transplantation With Tregs at MGH (PHASE1, PHASE2)
- Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
- Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal (PHASE4)
- Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation. (NA)
- Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants (PHASE4)
- Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic (PHASE4)
- Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |